Cytovale
Cyotvale offers IntelliSep, an FDA-cleared early sepsis detection test powered by the Cytovale System medical device.
- Total raised
- $229M
- Latest round
- Series Unknown
- Employees
- 121
Funding & revenue at Cytovale
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Total capital raised
$229M
15 known investors
Latest round
Series Unknown · $100M
Apr 2025
Investors
Growth signals
How fast Cytovale is adding people, roles, and audience.
Employees
121
Reported band 51-200
LinkedIn followers
16.3K
+16% year over year
Headcount change
- MoM
- 0%
- 0 people
- QoQ
- 0%
- 0 people
- 6mo
- -2.4%
- -3 people
- YoY
- -5.5%
- -7 people
- 2yr
- +3.4%
- +4 people
Team composition
Where Cytovale concentrates its people — a read on which function a fractional leader would plug into.
By function
- Engineering2924%
- Business Development1714%
- Research1311%
- Information Technology108%
- Quality Assurance76%
- Marketing54%
- Operations54%
- Sales43%
By region
- United States120
- California, United States72
- San Francisco Bay Area52
- San Francisco, CA21
- Los Angeles Metropolitan Area15
- Greater Chicago Area7
Inside Cytovale
What the business focuses on, where it operates, and how employees rate it.
Specialties
Categories
Markets
Jobs
0No open roles right now — view past roles below
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed August 16, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Cytovale, you can claim this page to manage and enhance it.